The Niche Episode 003 – BeiGene, ALS, Moderna, and Rheumatoid Arthritis

Today on The Niche, big deals in Chinese big-pharma as BeiGene raises another $2 billion, Biogen and Moderna both release papers on crucial clinical trials, and a new cell-type could play a pivotal role in rheumatoid arthritis.




Story References


Music by Luke Goodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.


Registered Users

Please login or register to continue.